Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Agents, Phytogenic
Carcinoma
Combined Modality Therapy
Disease-Free Survival
Fallopian Tube Neoplasms
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial
Neutropenia
Oncolytic Virotherapy
Oncolytic Viruses
Ovarian Neoplasms
Paclitaxel
Peritoneal Neoplasms
Prospective Studies
Reoviridae
Respiratory Tract Diseases

authors with profiles

Debra L Richardson
Joan L Walker